JMCP March 2025 Issue

In this Issue

Research

Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement

E Swart, S Peasah, Y Huang, M Bensink, M Greco, C Manolis, and C Good

Evaluating the uptake of a Global Initiative for Asthma guideline update in a commercially insured, value-based care population
L McInturff and S Smith

Integrated health system pharmacy role in adherence, persistence, and adverse effect management for oral chronic lymphocytic leukemia therapy
H Wyatt, S White, H Holloway, J DeClercq, A Zuckerman, L Choi, M Xue, K Carr, S Challgulla, K Yang, and C Renfro

Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States
K Kilgore, P Chan, C Teigland, S Wade, and I Mohammadi

Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States
S. Sullivan, S Chaturvedi, P Gautam, and A Arnaud

Research Brief

Use of health technology assessments in specialty drug coverage decisions by US commercial health plans

D Enright, E van Duijnhoven, D Ollendorf, and J Chambers

Receipt of Medicare Part D comprehensive medication reviews in older adults with dementia

A Coe, J Martindale, and J Bynum

Racial and Social Disparities in Medication Use 

The impact of patient characteristics and social drivers of health factors on oral oncolytic adherence

N Uyehara, V Nguyen, S Yu, Y Weng, A Son, P Patneedi, S Haidar, S Evans, E Oyekan, and N Ahuja

Perspectives on Value

The effectiveness and value of disease-modifying therapies for transthyretin amyloid cardiomyopathy
D Nikitin, J Wasfy, A Winn, F Raymond, K Shah, Sodam Kim, D Touchette, W Lee, M Richardson, D Rind, S Pearson, and F Agboola

LETTER

Thanks to JMCP Peer Reviewers, 2024

COMPLETE ISSUE 

JMCP, March 2025, Volume 31, Number 3

Subscribe for JMCP Issue Updates